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Background: Cilostazol, a phosphodiesterase inhibitor, inhibits platelet aggregation via effects on cAMP and reduces neointimal hyperplasia, which 
is implicated in stent restenosis.
However, the efficacy and safety of cilostazol in triple antiplatelet therapy (TAT) compared with conventional dual antiplatelet therapy (DAT) after 
percutaneous coronary intervention (PCI) is not well defined.
Methods: We performed a MEDLINE/EMBASE and CENTRAL search (January 1970-May 2011) of “cilostazol” and “randomized clinical trial” 
evaluating TAT versus DAT after PCI. The primary outcome was major adverse cardiovascular events (MACE) defined as death, myocardial infarction 
and target lesion revascularization (TLR). Secondary outcomes, including TLR and target vessel revascularization (TVR), and safety outcomes were 
evaluated.
Results: Of 108 studies that met inclusion criteria, 14 trials with 5527 patient years of followup were analyzed. Overall, TAT was associated with 
a significant reduction in the risk of MACE (Figure). TAT was associated with a significantly reduced risk of TLR (RR = 0.70; 95% CI 0.54-0.90) and 
TVR (RR = 0.74; 95% CI 0.59-0.91). Benefits were magnified in the diabetic subset. However, TAT was associated with a 182% increase in drug 
discontinuation due to adverse events.
Conclusion: In this largest, most comprehensive analysis to date, TAT resulted in significant reduction in the risk of MACE and restenosis related 
outcomes, with greatest benefit in diabetics, when compared with DAT alone.
 
